

Arden and Greater East Midlands Commissioning Support Unit in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from May 2016

For further details see *PACE Bulletin* Volume 10; Number 10 (July 2016)

SUMMARY OF PACEF DECISIONS: May 2016 Update

Device, Dressing or Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
<i>Eumocream</i> (glycerol 5% cream) (GlaxoSmithKline)	A glycerol based emollient for the treatment of dry or flaky skin conditions including eczema and dermatitis.	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for those considered to be at risk of conflagration from paraffin containing emollients and requiring a paraffin-free alternative.
Meprobamate 400mg tablets	For short-term use in anxiety	RED-RED Not included in the <i>Lincolnshire Joint Formulary</i> .
Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg (<i>Alzain</i>) (Dr Reddy's Laboratories UK Ltd)	For use as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of Generalised Anxiety Disorder (GAD) in adults.	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> within licensed indications only.
Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg (<i>Rewisca</i>) (Consilient Health Ltd)	For use as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of Generalised Anxiety Disorder (GAD) in adults.	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> within licensed indications only.
Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg (<i>Lecaent</i>) (Actavis UK Ltd)	For use as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of Generalised Anxiety Disorder (GAD) in adults.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg (<i>Pregabalin Zentiva</i>) (Zentiva)	For use as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of Generalised Anxiety Disorder (GAD) in adults.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Tramadol hydrochloride 37.5mg/paracetamol 325mg tablets (<i>Tramacet</i>) (Grünenthal)	For moderate to severe pain	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Tramadol hydrochloride 37.5mg/paracetamol 325mg effervescent tablets (<i>Tramacet Effervescent</i>) (Grünenthal)	For moderate to severe pain	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i>

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

What's new this month?

- **When prescribing pregabalin for the treatment of anything other than central or peripheral neuropathic pain, pregabalin should be prescribed as a lower cost brand, specifically as *Alzain* or *Rewisca*. Open generic scripts for pregabalin are still reimbursed at the higher *Lyrice* price; only branded prescribing of the preferred lower cost products will reduce prescribing costs.**
- **The MHRA have highlighted again the risk of diabetic ketoacidosis in patients taking the SGLT2 inhibitors, canagliflozin, dapagliflozin and empagliflozin.**
- **Meprobamate 400mg tablets are due to be withdrawn at the end of the year.**
- **The European Medicines Agency has started a review of canagliflozin after an increase in amputations, mostly toes, was observed in an ongoing clinical trial called CANVAS. At this stage in the trial, there are cases of lower limb amputation in both the canagliflozin and the placebo groups, although the incidence is higher in the canagliflozin groups. No increase in such amputations has been seen in 12 other completed canagliflozin trials. Healthcare professionals should ensure that diabetic patients are aware of the importance of routine footcare to avoid cuts or sores of the feet and to treat them promptly should they occur to prevent infection and ulceration. Patients at increased risk of amputation (such as those who have already had a previous amputation) should be carefully monitored. Doctors may consider stopping canagliflozin in patients who develop significant foot problems.**

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@ardengemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION